chrisvoncsefalvay/vaers-outcomes huggingface dataset:
THE JAB KILLED; This spontaneous report received from a consumer via social media (J&J corporate social media) via company representative concerned multiple patients of an unspecified age, race and ethnicity. The patient's weight, height, and medical history were not reported. The patients received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number and expiry were not reported) dose, start therapy date were not reported, 1 total administered for covid-19 prophylaxis. The batch number was not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported.  On an unspecified date, post receiving the vaccine, the jab killed the patients. The patients died from unknown cause of death. It was reported as "the jab killed her just like several in my family ... " It was unknown whether an autopsy was performed. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. This report was serious (Death). This case, from the same reporter is linked to 20220946006, 20220948266 and 20220948144. Sender's Comments: V0: 20220946018-covid-19 vaccine ad26.cov2.s-The jab killed. The event(s) has an unknown/unclear temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s). Therefore, this event(s) is considered unassessable. Reported Cause(s) of Death: UNKNOWN CAUSE OF DEATH
woke   up and could not move head and neck       Right hand fingers were curled and could not straighten
Weakness, fatigue, weak joints and muscles, sensitivity to light and flushed skin. Sudden.
18NOV93 pt came home from school w/fever (actual temp not taken per mom); 20NOV93 devel rash on face, progressed to back, trunk, arms & legs 24NOV93 mom stated no fever, rash still present, pt is feeling better;
Broke out in rash on left side of body and lymph nodes under arms are swollen around noon on 4/11/21. She stated that on 4/12/21  on the upper part of the rash there were four or so deep red spots that have appeared.
Before giving vaccines patient expressed that she was nervous about having vaccines but has never had any reactions in the past. Answered questions regarding vaccines and VIS was given to patient. Immediately after giving vaccines the patient turned  pale, and patient stated her stomach felt sick.  Laid patient down on the exam table.  Patient rest in exam room for 15 minutes and then she sat up and stayed for another 5 minutes.  No injury to patient. Provider notified and patient rechecked/monitored . Vitals Done . Patient observed and symptoms completely resolved. Able to walk out office on own will. Patient made aware to call if any further concerns. .
2 hours following vaccination, she developed chest tightness, hoarse voice, coughing, SOB, lasted 1.5 hours, partly improved with BENADRYL. In days following she continued to have numbness and weakness of left arm and leg.
This spontaneous report as received from a pharmacist refers to a patient of unknown age and gender who was enrolled in a market research program. On an unknown date the patient had seen or heard that the PNEUMOVAX 23 should be used as a second follow up vaccine to the initial PREVNAR 13 for most patients. The outcome of event was unknown. Additional information has been requested.
Patient had an Allergic Reaction  unknown cause . Onsite EMS was called vitals were taken BP 157/96 100% O2 room air  HR 92. Patient treated, transported by the EMS to the hospital.
4 days after 1st vaccine came out in a rash on tops of lower arms and lower legs. 10 days after that left parotid gland swelled up. Lasted a week, went down a week, up again. Happened 4 times on right side. 8 day break then right parotid gland swelled up, and still on its way down. Been going on for over 3 months now.
Local soreness, redness and swelling at injection site lasting 3 days. Fever for 2 days with highest 101.5, gradually decreasing by end of second day, accompanied by intermittent chills. Muscle aches in arms, shoulders, and back for 2 days. Extreme fatigue that gradually decreased over about  4 days.  Lack of appetite for one day.
Client C/O itching at site 45 mins after injection. She noticed swelling, redness, induration and fever in arm (all the way around( upper arm the next morning.
has multiple myeloma.; first dose of SHINGRIX on 12/23/2020 and 2 dose was not administered yet; This case was reported by a other health professional via call center representative and described the occurrence of multiple myeloma in a 41-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   On 23rd December 2020, the patient received the 1st dose of Shingrix. On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, less than 5 months after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced multiple myeloma (serious criteria GSK medically significant) and incomplete course of vaccination. On an unknown date, the outcome of the multiple myeloma and incomplete course of vaccination were unknown.   It was unknown if the reporter considered the multiple myeloma to be related to Shingrix.  Additional details provided were as follows: This case was reported by regulatory authority. The age at vaccination was not applicable for the 2nd dose. The patient had a cell transplant in April 2021. The patient had multiple myeloma. Till the time of reporting, patient did not received 2nd dose of Shingrix, which led to incomplete course of vaccination. The reporter consented to follow-up.
Patient came to office 2 days post immunizations (given 09/05/2002) in office 09/07/02. Had 5 cm reddened area around DTaP injection site, Pt was "whiney". No Temp, No Tx.
On Sunday evening , 2 days after the vaccine , the patient experience a complete loss of taste that lasted until that Tuesday ( 4 days after vaccination.) No treatment other than observation given.
This case was reported by a physician via call center representative and described the occurrence of type i hypersensitivity in a adult patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received the 2nd dose of SHINGRIX. On an unknown date, an unknown time after receiving SHINGRIX, the patient experienced type i hypersensitivity (serious criteria GSK medically significant). On an unknown date, the outcome of the type i hypersensitivity was unknown. It was unknown if the reporter considered the type i hypersensitivity to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported, but the age group was captured adult as per vaccine indication. The healthcare professional (HCP) reported that, the patient might have experienced a type 1 hypersensitivity reaction after receiving a dose of SHINGRIX. No further details were provided. The HCP did not give consent to follow-up.
Three days after immunization I  awoke at about 6am with a loud sound in my left ear and diminished hearing. I flushed a plug of wax from my ear without change in symptoms. I saw my primary MD, an internist who found that my tympanic membranes were clear. He diagnosed serous otitis media and put me on a prednisone pulse and taper. From day of onset (9/23 to completion of the taper 10/2  took the following daily dose in mg: 40, 30, 30, 30, 20, 20, 10, 20, 10, 5. My hearing was not much improved and I had a high-pitched tinnitus in the left ear. My internist referred me to an ENT Dr.  I saw Dr. on 10/12. An audiogram demonstrated low frequency hearing loss in my left hear and bilateral high pitch loss consistent with aging. He prescribed a second course of prednisone-40 mg per day for 5 days and then 20 mg/day for 5 days. On repeat visit 10/26 the low frequency deficit was gone, but tinnitus persisted. Dr. ordered a cranial MRI on 10/24 which demonstrated a 2-3mm focus of subtle non mosslike enhancement involving the  7th and 8th nerve complex.  I was referred by Dr. to his colleague Dr., a neurotologist at local hospital. He reviewed my history and the MRI. His diagnosis a "sudden sensorineural hearing loss with improvement and recommended a repeat MRI in one year  I still have a low level of tinnitus in that ear.
Information has been received from a consumer concerning her 8 year old daughter with no past medical history who in 1999 was vaccinated with a dose of varicella virus vaccine live (lot number not available). There was no concomitant medication. In approximately April 2004, the patient developed a mild case of chickenpox. Unspecified medical attention was sought, treatment was not required and laboratory tests were not performed. The reporter noted therapy with varicella virus vaccine live was discontinued. At the time of the report, the patient was getting better, but had not totally recovered. A product quality complaint was not involved. The reporter stated the physician may not be contacted. Additional information is not expected.
Pt states she had a headache and felt dizzy, two hours after the vaccine. Pt reports then feeling weak and went to sleep early. Pt woke this morning with the same symptoms.
persistent nausea, vomiting, dehydration, fever and chills, myalgias
No adverse effects reported; received improperly stored VARIVAX; This spontaneous report was received from lead medical assistant refers to a 14 year old patient of unknown gender. The patient's medical history, concurrent conditions, historical drugs and drug reactions/allergies were not reported. Concomitant medication included sterile diluent. On 11-APR-2019, the patient was vaccinated with improperly stored varicella virus vaccine live (oka/merck) (VARIVAX) lot # R023503 and expiry date 16-AUG-2020 (strength, dose, unit, route, anatomical location were not reported) for prophylaxis (product storage error). The vaccine was reconstituted with properly stored sterile diluent. The administered doses of the vaccines experienced temperature excursion from above 6 degree Fahrenheit (F) to 14 degree F (7.5 degree F) for five minutes. No previous temperature excursion was reported. The call was due to digital data logger. No adverse effects were reported. No product quality complaint (PQC) was involved.  This is one of several reports received from the same reporter.
1st dose on 2022, is late for 2nd; This case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 74-year-old male patient who received HAB (Twinrix) for prophylaxis.   Co-suspect products included hepatitis A and hepatitis B vaccine pre-filled syringe device (Twinrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   Previously administered products included Twinrix (1st dose received on 22nd august 2022 with batch number:J477Y expiry date:20th May 2023).   On an unknown date, the patient received the 2nd dose of Twinrix and Twinrix Pre-Filled Syringe Device. On an unknown date, unknown after receiving Twinrix and Twinrix Pre-Filled Syringe Device, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.     This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt date: 23-JAN-2023 Reporter comment: The pharmacist reported that a male patient received the 1st dose of Twinrix and was late for the 2nd dose. The reporter consented to follow up. Additional Supportive Information: Till the time of reporting, the patient did not receive 2nd dose of Twinrix, which led to incomplete course of vaccination.
hypoxic; shortness of breath; opacity in the mid and lower L lung; tachypnoea; tachycardia; This is a spontaneous report from a non-contactable other healthcare professional. A 65-year-old male patient received bnt162b2 (BNT162B2), dose 2 via an unspecified route of administration on 29Mar2021 (Lot Number: ER8734) as a single dose for covid-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient received the first dose of bnt162b2 (BNT162B2), dose 2 on an unspecified date for covid-19 immunization but reported to have had DOE for the past 3-4 days, has felt fatigued for the past week and his taste seems different over the past couple of days. It was reported that during the 15-minute waiting period after the injection, the patient began to experience shortness of breath as he was walking out to the front. He reports no issues with the vaccine as he was waiting. He denied rash, hives, welts, difficulty swallowing, wheezing, throat tightness, hoarseness, stridor, itching, lightheadedness, dizziness, facial swelling, lip swelling and tongue swelling. The patient complaints of shortness of breath. There was no treatment therapy provided. Follow up response to treatment was excellent (also reported as no treatment provided). The patient was discharged as stable to go home and follow up with PCP (primary care physician). He completed his second dose of Covid vaccine yesterday (29Mar2021). He presented to respiratory clinic earlier today (30Mar2021) and was noted to be hypoxic and was sent to ED. He reported DOE (dyspnea on exertion) for the past 3-4 days and has felt fatigued for the past week. He notes that his taste seems different over the past couple of days. CXR (chest x-ray) on an unspecified date in 2021 shows opacity in the mid and lower left lung. He is tachypnea, tachycardia, high normal WBC and afebrile on an unspecified date in 2021. The patient underwent lab tests and procedures which included chest x-ray showed opacity in the mid and lower L lung and white blood cell count was high normal on an unspecified date in 2021. The outcome of the events was unknown.  No follow-up attempts are possible. No further Information is expected.; Sender's Comments: Based on the close temporal association, a possible contributory role of the suspect vaccine BNT162B2 in triggering the onset of hypoxic cannot be excluded. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.
Fever, UrticariaPruritus, CHILLS, Narrative:  Other Relevant History:
pt recvd 1st dose of Engerix-B 26NOV91 p/1min pt exp lightheadness, dizziness, palpitations, sweating bronchospasm; extremities were cold & clammy; felt heaviness in limbs, tachycardia;
ms ptnt. She reported immediately after receiving the vaccine she had a shooting pain go down her neck and leg.  The pain in her leg lasted for an hour then went away.  She had no other complications between her 1st dose and 3 weeks later
1/4/2021  vaccination. About 5 pm, tingling and burning all over extremities. Sweating. Super dizzy at 8pm. Vertigo. Went to bed. Woke up . PCP wouldn't see me.  Went to Urgent Care. Afibrille. Vitals were stable. Rest, fluids. F/up with neurologist.
my son got bumps all over his legs right after the injection, within about 20 minutes. they looked like giant swollen bug bites. they then turned bright red and were a little less swollen but still all over his legs. it looks like hives or some sort of allergic reaction. he does not have any food allergies adn eats all sorts of foods, eggs, peanuts, everything .. no problems
4" raised red area to injection site that developed 8 days after vaccination. No pain but some itching
tested positive for covid 19, three days after receiving first dose; This spontaneous case was reported by a pharmacist and describes the occurrence of COVID-19 (tested positive for covid 19, three days after receiving first dose) in a 54-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006B21A) for COVID-19 vaccination.     No Medical History information was reported.    In March 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In March 2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced COVID-19 (tested positive for covid 19, three days after receiving first dose). At the time of the report, COVID-19 (tested positive for covid 19, three days after receiving first dose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   A pharmacist reported on a patient that had received his first dose of the vaccine on either 22-Mar-2021 or 23-Mar-2021. Three days after receiving the first dose, the patient contracted COVID-19.   Concomitant product use and treatment information was not provided.  The reporter consented to Safety followup.
Fever, Chills, Fatigue, Gas, Headache.  Hot, painful, hard, rash on upper arm at injection site
Began feeling like trying to catch a cold. Tired, tight chest, muscles sore. Symptoms continued for a couple weeks then a deep pain in side started.  Could not stand the side pain and went to ER. Scan showed enlarged cardiac silhouette. Further tests showed fluid completely surrounding heart with inflammation in duodenum. Was taking into surgery to have fluid from heart sac drained then a drain put in.
Information has been received from a physician concerning a 12 year old female patient with no pertinent medical history who in the end of October 2008 was vaccinated with the second dose of GARDASIL vaccine. There was no concomitant medication. The physician reported that patient has been having temporal headaches on right side of her head since 3 days after receiving the HPV vaccine. A computed axial tomography or magnetic resonance
Nurse documented that a pediatric/adolescent dose was administered when an Adult dose should have been given.
seriously ill; Initial information was received on 03-Dec-2020 regarding an unsolicited valid non-serious case received from a consumer/non-health care professional (patient's son/ daughter) via social media.  This case involves female patient (age not specified) who had seriously ill (illness), while she received INFLUENZA VACCINE.  Medical history, medical treatment(s), past vaccination(s) concomitant medication and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiry date were not reported) via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed a non-serious (severe) seriously ill (illness) (Unknown latency) after the administration of INFLUENZA VACCINE.  Laboratory data was not provided.  It was not reported if the patient received a corrective treatment.  At the time of reporting, the outcome of event was unknown.  There will be no information available on the batch number for this case.
PVCs started after the first COVID19 Pfizer vaccine. They were frequent, had associated symptoms of chest discomfort and breathlessness, and I went to the doctor. Their frequency/severity trended toward improving, but after the 2nd vaccine I was back to their original intensity/frequency. I do not have a history of similar. They are affecting my daily life. I've been referred to a Cardiologist.
Patient reports that hives, itching, and hand swelling began around 5:00pm on the same day of vaccine. (7/9/21) Patient reports taking OTC Benadryl. Patient seen 7/12/21 and a steroid shot provided.
Pt. developed swelling in the form of a noticeable bump at injection site a few seconds after vaccination. No redness seen. Pt. felt normal throughout his entire time at the store. I instructed pt. to wait about 15 minutes for observation and at the end of 15 minutes, the swelling came down noticeably and he still felt normal. I instructed pt. to visit PCP as soon as possible for follow-up.  No other symptoms reported.
Child was given Kinrix and Pediarix .   Call place to parent to let them know what to look for signs and symptoms
After last immunization given (HPV), pt body shaking approx 5-10 seconds, skin pale, lightheaded, dizzy.
I did not sleep for two days; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  An 81-year-old female patient received bnt162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 02Nov2023 as dose 1, single (Lot number: HF9300) at the age of 81 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Blood pressure high" (unspecified if ongoing). Concomitant medication(s) included: FELODIPINE taken for hypertension; NP THYROID taken for hypothyroidism; BISOPROLOL taken for hypertension. The following information was reported: INSOMNIA (non-serious) with onset Nov2023, outcome "unknown", described as "I did not sleep for two days". Therapeutic measures were not taken as a result of insomnia.  Additional information: The patient had the Pfizer COVID-19 Vaccine on 02Nov2023, and basically she did not sleep for several days. She stated that she had not had any COVID vaccines before this.
Received second dose Vaccine and developed, can't walk on legs anymore; This is a spontaneous report from a contactable consumer. A 36-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration in right arm on 16Jun2021 (Batch/Lot Number: EW0180) as dose 2, single for COVID-19 immunisation. The patient had no relevant medical history. There was nothing wrong with the patient. There were no concomitant medications. The patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) via unspecified route of administration in left arm on 17May2021 (lot number: EW0177) for COVID-19 immunisation. On 16Jun2021, the patient received the second dose Pfizer Covid 19 Vaccine and she developed, can't walk on legs anymore. The patient could not walk properly within 5 minutes of receiving the second dose Pfizer Covid 19 Vaccine. The reporter thought the not walking properly would subside but it was getting worse. The reporter stated that he needed to get the patient near the phone to answer the questions. The patient does not have a primary care physician. The reporter stated that the patient was too young for this. The patient can't even walk. There was no Investigation Assessment. Reporter wanted to know if anybody else called Pfizer regarding something similar to this walking problem. Outcome of the event was not recovered.  Follow-up attempts are completed. No further information is expected.
I was having really dry sinus' and at first I thought I may just because it was winter. The next day however I was having bad sinus pressure and a fever toward the end of the of the day. I took a COVID-19 home test, and it was positive and so I went to my pharmacy and got a test again. I had a runny nose as well. I did have some pain my ribs that developed and lingered past when the other symptoms stopped. I tried to see if stretching would help but ended up taking an anti-inflammatory and time to let that get better.
SOON AFTER ADMINISTRATION EXPERIENCED BURNING SENSATION STARTING LEFT SHOULDER RADIATING ACROSS CHEST AND DOWN  LEFT ARM.
Pt arm has been in pain ever since the vaccination. Pt has done an MRI and MD says they do not see anything. Pt says the Vaccine Administrator must have hit a muscle or tendon.
vax date 25MAY93 onset sx 5JUN93 arthralgias; h/a, t100; 7JUN93 sl better temp dec but now rash scattered; 8JUN93 feeling much worse again; 14JUN93 still not feeling well; acquired measles; devel bronchitis/sinus infect;